Glaukos (GKOS) Shares Outstanding (Diluted Average) (2014 - 2026)
Glaukos (GKOS) reported Shares Outstanding (Diluted Average) of $58.0 million for Q1 2026, up 2.45% year-over-year from $56.6 million in Q1 2025, and up 1.45% quarter-over-quarter from $57.2 million in Q4 2025.
Glaukos (GKOS) Shares Outstanding (Diluted Average) (2014 - 2026) Analysis & Trends
Glaukos (GKOS) has 9 years of Shares Outstanding (Diluted Average) data on file, last reported at $58.0 million in Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $58.0 million, up 2.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.0 million (up 2.45% YoY), and the FY2025 annual result was $57.2 million, up 8.41% from the prior year.
- Shares Outstanding (Diluted Average) grew to $58.0 million in Q1 2026 per GKOS's latest filing, from $57.2 million in the prior quarter.
- Over five years, Shares Outstanding (Diluted Average) peaked at $58.0 million in Q1 2026 and troughed at $47.2 million in Q2 2022.
- A 5-year average of $51.8 million and a median of $49.9 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
- The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Diluted Average) climbed 1.94% in 2022, then gained 14.23% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $47.4 million in 2022, then climbed by 2.08% to $48.4 million in 2023, then increased by 8.92% to $52.8 million in 2024, then grew by 8.41% to $57.2 million in 2025, then advanced by 1.45% to $58.0 million in 2026.
- Business Quant data shows GKOS's Shares Outstanding (Diluted Average) at $58.0 million in Q1 2026, $57.2 million in Q4 2025, and $57.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 1.75 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 386.50 Mn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 1.29 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 1.50 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 580.70 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 393.60 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 457.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Glaukos | 7.55 Bn | 7.45 Bn | 117.23 Mn | 58.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.02 Mn |
| Dec 31, 2025 | 57.19 Mn |
| Sep 30, 2025 | 57.40 Mn |
| Jun 30, 2025 | 56.92 Mn |
| Mar 31, 2025 | 56.64 Mn |
| Dec 31, 2024 | 52.76 Mn |
| Sep 30, 2024 | 55.04 Mn |
| Jun 30, 2024 | 50.17 Mn |
| Mar 31, 2024 | 49.58 Mn |
| Dec 31, 2023 | 48.43 Mn |
| Sep 30, 2023 | 48.68 Mn |
| Jun 30, 2023 | 48.28 Mn |
| Mar 31, 2023 | 47.88 Mn |
| Dec 31, 2022 | 47.44 Mn |
| Sep 30, 2022 | 47.35 Mn |
| Jun 30, 2022 | 47.21 Mn |
| Dec 31, 2021 | 46.42 Mn |
| Sep 30, 2021 | 46.26 Mn |
| Jun 30, 2021 | 46.31 Mn |
| Dec 31, 2016 | 36.46 Mn |